ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Open access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients.European journal of clinical pharmacology · 2020Pooled it
- A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.Cancer research communications · 2022Trial
- Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.The Journal of clinical investigation · 2022Trial
- A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.Molecular diagnosis & therapy · 2026Review
- Blood Based Biomarkers of DNA Methylation Associated with Platinum Resistance in High Grade Serous Ovarian Cancer.bioRxiv : the preprint server for biology · 2026Article
- Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Platinum-resistant ovarian cancer: From mechanisms to treatment strategies.Genes & diseases · 2026Review
- Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.bioRxiv : the preprint server for biology · 2026Article
- Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives.Biomedicines · 2025Review
- The Role of Epigenetic Modifications in Enhancing Bone Marrow Transplantation Efficacy in Cancer.Advances in experimental medicine and biology · 2025Review
- Drug resistance in ovarian cancer: from mechanism to clinical trial.Molecular cancer · 2024Review
- DNA methylation characteristics associated with chemotherapy resistance in epithelial ovarian cancer.Heliyon · 2024Article
- Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.Health science reports · 2023Article
- Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.Journal for immunotherapy of cancer · 2022Article
- Article
- Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine.Frontiers in oncology · 2022Article
- Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Daniela MateiNorthwestern University Feinberg School of Medicine, Chicago, Illinois. daniela.matei@northwestern.edu.
Sharad GhamandeGeorgia Cancer Center at Augusta University, Augusta, Georgia.
Lynda RomanUSC Norris Comprehensive Cancer Center, Los Angeles, California.
Angeles Alvarez SecordDepartment of Obstetrics and Gynecology, Duke Cancer Institute, Division of Gynecologic Oncology, Durham, North Carolina.
John NemunaitisUniversity of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Merry Jennifer MarkhamUniversity of Florida College of Medicine, Gainesville, Florida.
Kenneth P NephewIndiana University, Bloomington, Indiana.
Simone JueligerAstex Pharmaceuticals, Cambridge, United Kingdom.
Aram OganesianAstex Pharmaceuticals Inc., Pleasanton, California.
Sue NaimAstex Pharmaceuticals Inc., Pleasanton, California.
Xiang Yao SuAstex Pharmaceuticals Inc., Pleasanton, California.
Harold KeerAstex Pharmaceuticals Inc., Pleasanton, California.
Mohammad AzabAstex Pharmaceuticals Inc., Pleasanton, California.
Gini F FlemingUniversity of Chicago Medicine, Chicago, Illinois.
Northwestern University · US
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MGeorgia CaResUG1CA189851 · NCI · AUGUSTA UNIVERSITY · PI Anand P Jillella · 2014 to 2026
$13.3MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MONCOLOGYU10CA027525 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GOLDSTEIN, LORI J · 1985 to 2013
$6.2MCWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating SiteU10CA180853 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERDS, AARON THOMAS, MACHTAY, MITCHELL · 2014 to 2018
$6.2MMCG Minority-Based Community Clinical Oncology ProgramU10CA107586 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI GHAMANDE, SHARAD A. · 2004 to 2014
$5.3MStanford University NCTN- Network Lead Academic SiteU10CA180816 · NCI · STANFORD UNIVERSITY · PI COUTRE, STEVEN EDWARD, LE, QUYNH-THU XUAN · 2014 to 2018
$2.8MNCTN Deep South Research ConsortiumU10CA180855 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BJORNSTI, MARY-ANN, FALKSON, CARLA I · 2014 to 2018
$2.6MBuilding upon a tradition of excellence. The NCTN at Indiana UniversityU10CA180795 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI MILLER, KATHY D. · 2014 to 2018
$2.6MAn Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian CancerR01CA182832 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MATEI, DANIELA E, NEPHEW, KENNETH P · 2014 to 2018
$1.6MNCI NIH HHS P30 CA006927NCI NIH HHS R01 CA182832NCI NIH HHS R21 CA133877NCI NIH HHS U01 CA221242NCI NIH HHS U10 CA107586NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180795NCI NIH HHS U10 CA180853NCI NIH HHS U10 CA180855NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189851NICHD NIH HHS K12 HD085817
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug Resistance, NeoplasmAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCarboplatinDrug MonitoringFemaleHumansMiddle AgedOvarian NeoplasmsPlatinum CompoundsRecurrenceRetreatmentAzacitidineCarboplatinguadecitabinePlatinum Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.